European survey of diagnosis and management of the polycystic ovary syndrome: Results of the ESE PCOS Special Interest Group's Questionnaire

European Journal of Endocrinology

Volumn 171, Issue 4, 2014, Pages 489-498

  Conway, Gerard ^a   Dewailly, Didier ^b   Diamanti Kandarakis, Evanthia ^c   Escobar Morreale, Hector F ^d   Franks, Steven ^e   Gambineri, Alessandra ^f   Kelestimur, Fahrettin ^g   Macut, Djuro ^h   Micic, Dragan ^h   Pasquali, Renato ^f   Pfeifer, Marija ⁱ   Pignatelli, Duarte ^j   Pugeat, Michel ^k   Yildiz, Bulent O ^l  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g ERCIYES UNIVERSITY   (Turkey)

^h UNIVERSITY OF BELGRADE   (Serbia)

ⁱ UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^j HOSPITAL DE SÃO JOÃO   (Portugal)

^k UNIVERSITÉ LYON 1   (France)

^l HACETTEPE UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; CLOMIFENE CITRATE; METFORMIN; MUELLERIAN INHIBITING FACTOR; TESTOSTERONE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CLOMIFENE; FERTILITY PROMOTING AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; DIFFERENTIAL DIAGNOSIS; ESTHETIC SURGERY; EUROPE; FEMALE; FEMALE INFERTILITY; HIRSUTISM; HUMAN; HYPERANDROGENISM; INFERTILITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL CONTRACEPTIVE USE; OVARY POLYCYSTIC DISEASE; PRESCRIPTION; QUESTIONNAIRE; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; BLOOD; CLINICAL PRACTICE; ENDOCRINOLOGY; HEALTH CARE SURVEY; MEDICAL SOCIETY; MENSTRUATION DISORDER; MIDDLE AGED; RISK REDUCTION; STATISTICS;

ADULT; ANDROGENS; BIOLOGICAL MARKERS; CLOMIPHENE; CONTRACEPTIVES, ORAL; DIAGNOSIS, DIFFERENTIAL; ENDOCRINOLOGY; EUROPE; FEMALE; FERTILITY AGENTS, FEMALE; HEALTH CARE SURVEYS; HIRSUTISM; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; MALE; MENSTRUATION DISTURBANCES; METFORMIN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYCYSTIC OVARY SYNDROME; QUESTIONNAIRES; RISK REDUCTION BEHAVIOR; SOCIETIES, MEDICAL; TESTOSTERONE;

EID: 84907217885     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0252     Document Type: Article

References (43)

1. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam. Boston: Blackwell Scientific Publications, 1992.
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47. (doi:10.1093/humrep/deh098)
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009 91 456-488. (doi:10.1016/j.fertnstert.2008.06.035)
4. Diamanti-Kandarakis E & Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012 33 981-1030. (doi:10.1210/er. 2011-1034)
5. Pasquali R & Gambineri A. Glucose intolerance states in women with the polycystic ovary syndrome. Journal of Endocrinological Investigation 2013 36 648-653. (doi:10.1007/BF03346757)
6. Moran LJ, Misso ML, Wild RA & Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010 16 347-363. (doi:10.1093/humupd/dmq001)
7. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility 2012 97 28-38.e25. (doi:10.1016/j.fertnstert.2011. 09.024)
8. Dunaif A & Fauser BC. Renaming PCOS -a two-state solution. Journal of Clinical Endocrinology and Metabolism 2013 98 4325-4328. (doi:10.1210/ jc.2013-2040)
9. Cussons AJ, Stuckey BG, Walsh JP, Burke V & Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical Endocrinology 2005 62 289-295. (doi:10.1111/j.1365-2265.2004.02208.x)
10. Stein IF & Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology 1935 29 181.
11. Doll I, Doll R & Buhling KJ. Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynaecologists with a review on literature. Archives of Gynecology and Obstetrics 2012 285 689-697. (doi:10.1007/s00404-011-2014-7)
12. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update 2012 18 146-170. (doi:10.1093/humupd/dmr042)
13. Sathyapalan T & Atkin SL. Recent advances in cardiovascular aspects of polycystic ovary syndrome. European Journal of Endocrinology 2012 166 575-583. (doi:10.1530/EJE-11-0755)
14. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A & Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Human Reproduction 2011 26 3123-3129. (doi:10.1093/ humrep/der297)
15. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ & Escobar Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update 2014 20 334-352. (doi:10.1093/humupd/dmt061)
16. Rosner W, Auchus RJ, Azziz R, Sluss PM & Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism 2007 92 405-413. (doi:10.1210/jc.2006-1864)
17. Rosner W, Vesper H & Endocrine Society; and the endorsing organizations. Toward excellence in testosterone testing: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2010 95 4542-4548. (doi:10.1210/jc.2010-1314)
18. O'Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, Stewart PM, Tomlinson JW & Arlt W. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. Journal of Clinical Endocrinology and Metabolism 2014 99 1027-1036.
19. Allolio B & Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 2006 91 2027-2037. (doi:10.1210/jc.2005-2639)
20. Pugeat M, Déchaud H, Raverot V, Denuzière A, Cohen R, Boudou P & French Endocrine Society. Recommendations for investigation of hyperandrogenism. Annales d'Endocrinologie 2010 71 2-7. (doi:10.1016/j.ando.2009.12.007)
21. Legro RS, Schlaff WD, Diamond MP, Coutifaris C, Casson PR, Brzyski RG, Christman GM, Trussell JC, Krawetz SA, Snyder PJ et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. Journal of Clinical Endocrinology and Metabolism 2010 95 5305-5313. (doi:10.1210/ jc.2010-1123)
22. Fanelli F, Belluomo I, Di Lallo VD, Cuomo G, De Iasio R, Baccini M, Casadio E, Casetta B, Vicennati V, Gambineri A et al. Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. Steroids 2011 76 244-253. (doi:10.1016/j. steroids.2010.11.005)
23. Janse F, Eijkemans MJC, Goverde AJ, Lentjes EG, Hoek A, Lambalk CB, Hickey TE, Fauser BC & Norman RJ. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. European Journal of Endocrinology 2011 165 925-933. (doi:10.1530/EJE-11-0482)
24. Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995 333 853-861. (doi:10.1056/NEJM199509283331307)
25. Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1236. (doi:10.1056/NEJMra041536)
26. Yildiz BO, Knochenhauer ES & Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 162-168. (doi:10.1210/jc.2007-1834)
27. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN & PCOS/ Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 66-71. (doi:10.1210/jc.2004-0229)
28. Ezeh U, Yildiz BO & Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 E1088-E1096. (doi:10.1210/jc. 2013-1295)
29. Pasquali R. Obesity and androgens: facts and perspectives. Fertility and Sterility 2006 85 1319-1340. (doi:10.1016/j.fertnstert.2005.10.054)
30. Borruel S, Fernández-Durán E, Alpañés M, Martí D, Alvarez-Blasco F, Luque-Ramírez M & Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). Journal of Clinical Endocrinology and Metabolism 2013 98 1254-1263. (doi:10.1210/ jc.2012-3698)
31. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S et al. Obesity and sex steroid changes across puberty: evidence formarked hyperandrogenemia in pre-and early pubertal obese girls. Journal of Clinical Endocrinology and Metabolism 2007 92 430-436. (doi:10.1210/jc.2006-2002)
32. Repaci A & Gambineri A. The role of low-grade inflammation in the polycystic ovary syndrome. Molecular and Cellular Endocrinology 2011 335 30-41. (doi:10.1016/j.mce.2010.08.002)
33. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale H, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
34. de Groot PC, Dekkers OM, Romijn JA, Dieben SW & Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human Reproduction Update 2011 17 495-500. (doi:10.1093/humupd/dmr001)
35. Bishop SC, Basch S & Futterweit W. Polycystic ovary syndrome, depression and affective disorders. Endocrine Practice 2009 15 475-482. (doi:10.4158/EP09083.RAR)
36. Jedel E, Waern M, Gustafson D, Landén M, Eriksson E, Holm G, Nilsson L, Lind AK, Janson PO & Stener-Victorin E. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Human Reproduction 2010 25 450-456. (doi:10.1093/humrep/dep384)
37. Açmaz G, Albayrak E & Ipek Müderris I. Level of anxiety, depression, self-esteem, social anxiety, and quality of life among the women with polycystic ovary syndrome. Scientific World Journal 2013 2013 851815.
38. Moran LJ, Deeks AA, Gibson-Helm ME & Teede HJ. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction 2012 27 2082-2088. (doi:10.1093/ humrep/des114)
39. Livadas S, Chaskou S, Kandaraki AA, Skourletos G, Economou F, Christou M, Boutzios G, Karachalios A, Zerva A, Xyrafis X et al. Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. Clinical Endocrinology 2011 75 698-703. (doi:10.1111/j.1365-2265.2011.04122.x)
40. Thomson RL, Buckley JD, Lim SS, Noakes M, Clifton PM, Norman RJ & Brinkworth GD. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility 2009 94 1812-1816. (doi:10.1016/j. fertnstert.2009.11.001)
41. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013 98 4565-4592. (doi:10.1210/ jc.2013-2350)
42. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM & Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 1105-1120. (doi:10.1210/jc. 2007-2437)
43. Costello M, Shrestha B, Eden J, Sjoblom P & Johnson N. Insulinsensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2007 CD00555.